With newer biologics enriching the armentarium of Dermatologists almost everyday,it is often difficult to recollect all the information at a time.This powerpoint helps to summarise the pathogenesis of psoriasis as well asdifferent aspects of use of biologics in a nutshell.
13. ELIGIBILITY CRITERIA
A. Severe disease
B. Fulfil at least one of the following clinical
categories
When phototherapy or alternative standard
systemic therapy are contraindicated
Intolerant to standard systemic therapy
Unresponsive to standard systemic therapy
Have significant comorbidity which precludes
the use of standard systemic therapy
Severe,unstable, life threatening disease
14. STEPS WHILE STARTING
BIOLOGIC AGENT
1)Counselling
2)Pre-treatment history &
investigations
3)Planning vaccination
4)Choosing biologics
15. WHICH ONE TO CHOOSE
1) Rapidity of response
desired
2) Comorbidities
3) Facilities
4) Administering
biologic
5) Cost
6) Follow up
16. WHICH ONE TO CHOOSE
1) Rapidity of response
desired
2) Comorbidities
3) Facilities
4) Administering
biologic
5) Cost
6) Follow up
17. CHOICE OF BIOLOGICS WITH COMORBIDITIES
COMORBIDITIES BIOLOGIC
Tubeculosis Secukinumab
HBV/HCV Secukinumab
HIV Etanercept
Psoriatic arthropathy Adalimumab/Secukinumab
Multiple sclerosis Secukinumab
CHF Secukinumab
18. CHOICE OF BIOLOGICS WITH COMORBIDITIES
COMORBIDITIES BIOLOGIC
Coronary artery disease Anti- TNFα therapy
IBD Anti- TNFα therapy
Autoimmune disease Use biologics with caution
CLD of noninfectious etiology Etanercept/Adalimumab
CRF Etanercept
Cancer No data available
Obesity Secukinumab
19. AT A GLANCE
DRUG
DOSING
SCHEDULE TOXICITY
ETANERCEPT 25/50 mg twice weekly sc for 12
weeks and then weekly
Inj site reactions,
URTI,Lupus like
syndrome,CHF
worsening,TB reactivation
ADALIMUMAB 80 mg on D1 f/b 40 mg every
other week
Inj site reaction,reactivation
of TB
INFLIXIMAB 3-5 mg/kg 0,2,6 wks and 8 wkly
thereafter
Infusion
reactions,ADA,reactivation
of TB
ITOLIZUMAB 1.6mg/kg as IV infusion every 2
wk for 12 wk f/b once in 4 wk for
24 wk
Acute infusion
reaction,diarrohoea
SECUKINUMAB 300 mg sc 0,1,2,3,4 wk f/b
monthly maintainence dose
Nasopharyngitis,
Candidiasis,
Neutropenia
20.
21.
22. COMBINATION WITH BIOLOGICS
BIOLOGIC NBUVB MTX ACITRETIN CsA
ETANERCEPT Rescue
therapy
Faster
clearence
Decreased dose Rescue therapy
(?)
ADALIMUMAB Rescue/bridg
e/concomitan
t/maintenanc
e
No studies Decreased dose Rescue therapy
(?)
INFLIXIMAB Rescue
therapy (?)
Decreased ADA Rescue/
Maintenance
therapy
Avoid
SECUKINUMAB No studies No studies No studies No studies
23. BIOLOGICS IN SPECIAL SITUATIONS
ETARNACEPT
ADALIMUMAB
USTEKINUMAB
INFLIXIMAB
ETARNACEPT
ADALIMUMAB
INFLIXIMAB
24. SWITCHING BIOLOGICS
INEFFICACY ADVERSE EFFECTS
Can be switched over
to different drug of
same class or new
class
Switched over to drug of
NEW CLASS (infectious
complications, CHF,
multiple sclerosis while on
TNFα blocker)
OR
drug of SAME CLASS(e.g-
in case of ADA)
25. INDICATIONS OF
STOPPING BIOLOGICS
a) Fail to achieve adequate response
b) A serious adverse effect
c) Pregnancy(temporary withdrawal)
d) Elective surgical
procedure(temporary withdrawal)
28. TAKE HOME MESSAGE
Psoriasis has tremendous psychosocial impact.
Insights into immunopathogenesis of psoriasis
have led to discovery of numerous new
therapies.
Biologics are a better treatment option with
improved outcomes
Amongst all the biologics, SECUKINUMAB
provides the highest efficacy and QOL
response with a favourable safety profile